DARPA DEFUSE Proposal (2018)

Authored by Peter Daszak (EcoHealth Alliance) in partnership with Ralph Baric (UNC) + Shi Zhengli (Wuhan Institute of Virology). Sought $14.2M federal funding under DARPA PREEMPT program. **Explicit content:** insert human-specific proteolytic cleavage sites — specifically furin cleavage sites — into novel bat coronaviruses. Identify viral strains exploiting DC-SIGN pathway. Introduce key RBD residues to test ACE2 affinity in humanized mice. Suppress bat interferon responses. **DARPA rejected** citing safety, Dual Use Research of Concern (DURC), failure to address Ethical/Legal/Social Issues. Despite knowledge across 15 federal agencies (including NIH Rocky Mountain Lab listed as partner), concealed from public during critical early years of pandemic. [2026-05-06 COVID Wealth Transfer Audit extension] DARPA→Moderna $25M 2013 grant funded foundational mRNA technology subsequently commercialized via Operation Warp Speed (`operation_warp_speed_contractor_ledger`) yielding $1.5B BARDA contract + record IPO valuation. Pattern: DoD-seeded biotechnology pre-positioned 7 years before COVID-19 commercialization trigger. Cross-reference Event 201 (October 2019 — funded by Open Philanthropy Project + co-hosted by WEF + Gates Foundation; explicitly modeled pandemic-financial-crisis injects mirroring BlackRock's August 2019 Going Direct paper, demonstrating multi-node pre-alignment on impending liquidity interventions per audit Finding 49) — DARPA-DEFUSE 2018 is upstream of both the biological-substrate firing and the financial-architecture default-programming. **Report #84 (May 7 2026 MV Hondius audit - adversarial null cross-reference):** Andes virus has no DEFUSE-equivalent program in the public record. The MV Hondius cluster traces to a routine pre-boarding rodent exposure near Ushuaia, not to any high-containment laboratory program. The lab-leak architecture the engine tracks does NOT extend to this event. **[Report — US Biodefense Apparatus, Sept 2026 — origins correction, receipts attached]** DEFUSE was authored by EcoHealth Alliance for the DARPA PREEMPT solicitation.^[1] The rejection document records a requested total of $14,209,245 (Phase I $8,411,546; Phase II $5,797,699); DARPA's Biological Technologies Office judged the proposal 'selectable' but did not recommend funding, citing that the work potentially involved Gain-of-Function/DURC research while the proposal itself neither assessed those risks nor presented a DURC mitigation plan, and hardly addressed ethical, legal and social issues.^[2] **Position precision (previously absent from this node):** the submitted proposal specifies 'human specific proteolytic cleavage sites' at the S2' position, while earlier drafts specify positions corresponding to the S1/S2 junction — and it is at S1/S2 that the SARS-CoV-2 furin cleavage site sits.^[3] **Execution is not established.** US Right to Know, which published the documents and argues the laboratory case, states that DARPA rejected the project and that whether the research was funded through other means remains unknown, and that the documents do not prove a step-by-step account of how SARS-CoV-2 was generated.^[4] **Agency knowledge, corrected:** the engine previously recorded knowledge across fifteen federal agencies as concealment. The primary record is narrower and dated — Senator Rand Paul, 9 April 2024: at least fifteen agencies participated in a DARPA-hosted 'PREEMPT Proposers Day', and the project's existence was not revealed to the public until 2021. ASPR is among the agencies written to.^[5] **The natural-acquisition leg, recorded so the fork is not one-sided:** molecular features in European SARS-related bat coronaviruses indicate that a single nucleotide exchange may suffice to enable furin cleavage,^[6] and furin cleavage sites occur naturally across coronavirus spike proteins, first identified in a mouse coronavirus.^[7] **Engine reading:** the proposal is a confirmed substrate of intent whose stated insertion position does not match SARS-CoV-2 in the submitted version and does match it in the drafts; execution is unevidenced in either direction. Per darpa (two arms: classified CRADA transfer alongside the open solicitation record) and disclosure_architecture (zero of twelve US disclosure episodes scored cleanly voluntary-at-cost), the DARPA rejection document is substrate and is NOT treated as arbiter of whether the work occurred; per foia_administrative the absence of a funding record is equally not treated as proof of concealment. Apex Superposition: (b) structural-recurrence load-bearing — the solicitation record documents state biotechnology capability regardless of this proposal's fate; (c) collective-psychology operative — an origins verdict in either direction performs consensus-definition work; (a) intentional-cabal NOT supported on the present record. Held; scale not stamped; name no holder. The open fork is carried in divergences as 'Was DEFUSE Executed?'.